Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week randomized, multicenter, single blinded, international study to evaluate the effect of reminder notifications and motivational/adaptive messaging on treatment adherence of COPD subjects receiving Ultibro Breezhaler treatment using the Concept2 inhaler for dose tracking

Next Previous
Trial Profile

A 24-week randomized, multicenter, single blinded, international study to evaluate the effect of reminder notifications and motivational/adaptive messaging on treatment adherence of COPD subjects receiving Ultibro Breezhaler treatment using the Concept2 inhaler for dose tracking

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glycopyrrolate/indacaterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors Novartis Pharma A.G.

    • Most Recent Events

    • 28 Feb 2019 This trial has been Suspended in Netherlands, according to European Clinical Trials Database.
    • 14 Feb 2019 This trial has been Changed to Suspended to discontinued in Austria (End date: 2019-01-24) , according to European Clinical Trials Database.
    • 28 Nov 2018 This trial has been Suspended in Austria, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top